Stock News Alert: Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) stock observed trading 0.73% off 52-week high price. On the other end, the stock has been noted 36.15% away from low price over the last 52-weeks. The stock disclosed a move of 14.11% away from 50 day moving average and 19.23% away from 200 day moving average. Moving closer, we can see that shares have been trading 6.52% off 20-day moving average. It has market cap of $132.94B and dividend yield of 2.14%.

On Jan. 10, 2020, Eli Lilly and Company (NYSE:LLY) reported a definitive agreement for Lilly to acquire Dermira for $18.75 per share, or approximately $1.1 billion, in an all-cash transaction. Dermira is a biopharmaceutical company dedicated to developing new therapies for chronic skin conditions.

The acquisition will expand Lilly’s immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity that is being evaluated in a Phase 3 clinical development program for the treatment of moderate-to-severe atopic dermatitis in adolescent and adult patients, ages 12 years and older. Lebrikizumab was granted Fast Track designation from the U.S. Food and Drug Administration (FDA) in December 2019. The acquisition of Dermira will also expand Lilly’s portfolio of marketed dermatology medicines with the addition of QBREXZA® (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating).

People suffering from moderate-to-severe atopic dermatitis have significant unmet treatment needs, and we are excited about the potential that lebrikizumab has to help these patients, said Patrik Jonsson, Lilly senior vice president and president of Lilly Bio-Medicines The acquisition of Dermira is consistent with Lilly’s strategy to augment our own internal research by acquiring clinical phase assets in our core therapeutic areas and leveraging our development expertise and commercial infrastructure to bring new medicines to patients. This acquisition provides an opportunity to add a promising Phase 3 immunology compound for atopic dermatitis, while also adding an approved dermatology treatment for primary axillary hyperhidrosis. We look forward to completing the acquisition and continuing Dermira’s excellent work.

The USA based company Eli Lilly and Company moved with change of 1.53% to $138 with the total traded volume of 4169695 shares in recent session versus to an average volume of 3.27M shares. The stock was observed in the 5 days activity at 4.73%. The one month performance of stock was 14.38%. LLY’s shares are at 29.07% for the quarter and driving a 19.03% return over the course of the past year and is now at 5.00% since this point in 2018.  Right now the stock beta is 0.22. The average volatility for the week and month was at 1.52% and 1.53% respectively. There are 963.34M shares outstanding and 958.35M shares are floated in market.

Leave a Reply

Your email address will not be published. Required fields are marked *